Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK4532990
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
GSK4532990 is an investigational GalNAc-conjugated small interfering RNA (siRNA) therapeutic designed to target and inhibit the expression of hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), a liver protein implicated in the development and progression of non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease (ALD)[1][2][5][7]. By reducing HSD17B13 expression through RNA interference, the drug aims to decrease inflammation, fat accumulation, and fibrosis in the liver. It is administered via subcutaneous injection. The drug was originally developed by Arrowhead Pharmaceuticals as ARO-HSD and later licensed to GSK for further development outside Greater China[2][6]. Clinical trials are ongoing for both NASH and ALD[1][3][4].
- Other names
- GSK 4532990GSK4532990GSK-4532990ARO-HSD
02
Targets
HSD17B13 (17β-Hydroxysteroid Dehydrogenase Type 13)
Beyond the preview
Go deeper on GSK4532990.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK4532990.